Loading
Taking 250 mg of abiraterone with a low-fat breakfast gives the same PSA response and testosterone suppression as the standard 1,000 mg fasting, because food increases absorption several-fold, so a quarter of the drug treats each man. The label still says fasting and no company promotes the food-effect dose, so adoption is patchy.
A randomised trial (Szmulewitz et al., JCO 2018) showed 250 mg abiraterone with a low-fat breakfast was non-inferior to 1,000 mg fasting on PSA response and testosterone suppression in metastatic castration-resistant prostate cancer, because food increases absorption several-fold. NCCN guidelines list the food-effect dose as an option. Adoption is patchy because the label still says fasting and because there is no commercial incentive to promote it. Generic abiraterone makes the absolute saving smaller in the US but large where the branded product is still used or where patients pay out of pocket.
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for Abiraterone acetate in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Abiraterone acetate in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Abiraterone acetate in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Wrong doses, Androgen deprivation & AR pathway inhibitors, Prices and value, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.